CornelissenB-board-2026

Bart Cornellissen

Chief Financial Officer, Xencor / United States

Bart Cornelissen is Chief Financial Officer of Xencor, a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. He is a strategic finance leader with more than two decades of experience across pharmaceuticals, biotechnology, and global health in the United States and Europe. He partners with executive teams and boards on strategic planning, capital formation and allocation, portfolio and investment decisions, and business development to drive growth, accelerate innovation, and create long-term value.

At Xencor, Mr. Cornelissen leads the finance, IT, procurement, and facilities functions. Before that, he was vice president of corporate finance at Seagen where he led corporate finance through rapid global growth, major licensing transactions, and the company’s $44 billion acquisition by Pfizer.

Mr. Cornelissen’s commitment to health equity comes from his experience working in global health. At the Gates Foundation, he was finance lead for the malaria and neglected tropical disease teams where he guided a large portfolio of drug and vaccine development partnerships. He later served as vice president of finance at the END Fund, a philanthropic initiative dedicated to ending neglected tropical diseases.

Mr. Cornelissen began his career at Novartis in Basel and later held finance leadership roles at DSM in Switzerland, Germany, and Austria. Outside of his CFO role, Mr. Cornelissen is an advisor to growth-stage startups, including Frontier Medicines and Discovery Biotech.